Trends and Outcomes in Simultaneous Liver and Kidney Transplantation in Australia and New Zealand.


Journal

Transplantation proceedings
ISSN: 1873-2623
Titre abrégé: Transplant Proc
Pays: United States
ID NLM: 0243532

Informations de publication

Date de publication:
Historique:
received: 21 05 2020
revised: 27 06 2020
accepted: 08 08 2020
pubmed: 17 9 2020
medline: 20 4 2021
entrez: 16 9 2020
Statut: ppublish

Résumé

Rates of simultaneous liver and kidney transplantation (SLKT) have increased, but indications for SLKT remain poorly defined. Additional data are needed to determine which patients benefit from SLKT to best direct use of scarce donor kidneys. Data were extracted from the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) database for all SLKT performed until the end of 2017. Patients were divided by pretransplant dialysis status into no dialysis before SLKT (preemptive kidney transplant) and any dialysis before SLKT (nonpreemptive). Baseline characteristics and outcomes were compared. Between 1989 and 2017, inclusive, 84 SLKT procedures were performed in Australia, of which 24% were preemptive. Preemptive and nonpreemptive SLKT recipients did not significantly differ in age (P = .267), sex (P = .526), or ethnicity (P = .870). Over a median follow-up time of 4.5 years, preemptively transplanted patients had a statistically equivalent risk of kidney graft failure (hazard ratio (HR) 1.83, 95% confidence interval [CI]: 0.36-12.86, P = .474) and all-cause mortality (HR 1.69, 95% CI: 0.51-5.6, P = .226) compared to nonpreemptive patients. Overall, 1- and 5-year survival rates for all SLKTs were 92% (95% CI: 86-96) and 60% (95% CI: 45-75), respectively. Kidney graft and overall patient survival were similar between patients with preemptive kidney transplant and those who were dialysis dependent.

Identifiants

pubmed: 32933766
pii: S0041-1345(20)32695-6
doi: 10.1016/j.transproceed.2020.08.030
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

136-140

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Douglas Drak (D)

National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia. Electronic address: ddra8845@uni.sydney.edu.au.

Nishanta Tangirala (N)

Nephrology Department, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.

Michael Fink (M)

Department of Surgery, Austin Health, University of Melbourne, Melbourne, Victoria, Australia.

Leon A Adams (LA)

Medical School, The University of Western Australia, Perth, Western Australia, Australia; Department of Hepatology, Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands, Perth, Western Australia, Australia.

Jonathan Fawcett (J)

Princess Alexandra Hospital, Brisbane, Queensland, Australia; School of Medicine, The University of Queensland, Brisbane, Australia.

Gary P Jeffrey (GP)

Medical School, The University of Western Australia, Perth, Western Australia, Australia; Department of Hepatology, Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands, Perth, Western Australia, Australia.

Mandy Byrne (M)

Victorian Liver Transplant Unit, Heidelberg, Victoria, Australia.

Geoffrey McCaughan (G)

Central Clinical School, University of Sydney, Sydney, New South Wales, Australia; Liver Injury and Cancer, Centenary Institute, Camperdown, New South Wales, Australia.

Steve Chadban (S)

Nephrology Department, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia; Central Clinical School, University of Sydney, Sydney, New South Wales, Australia.

Kate Wyburn (K)

Nephrology Department, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia; Central Clinical School, University of Sydney, Sydney, New South Wales, Australia.

Germaine Wong (G)

Centre for Kidney Research, School, Children's Hospital at Westmead, Westmead, New South Wales, Australia.

Wai H Lim (WH)

Medical School, The University of Western Australia, Perth, Western Australia, Australia; Department of Renal Medicine, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.

David M Gracey (DM)

Nephrology Department, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia; Central Clinical School, University of Sydney, Sydney, New South Wales, Australia; Holdsworth House Medical Practice, Sydney, New South Wales, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH